SARS-CoV-2 Infection and the Development of Therapeutics
- 1st Edition - April 1, 2027
- Latest edition
- Editors: Amit Kumar Nayak, Amal Kumar Dhara
- Language: English
SARS-CoV-2 Infection and the Development of Therapeutics provides thorough insights into the SARS-CoV-2 virus, viral infection and transmission, the emergence of variants, need f… Read more
End of Summer Sale
Save up to 30% off
Bright savings for research, study, and discovery
Description
Description
SARS-CoV-2 Infection and the Development of Therapeutics provides thorough insights into the SARS-CoV-2 virus, viral infection and transmission, the emergence of variants, need for testing and rapid diagnosis, and the development of effective therapeutic interventions. This book begins with an introduction that highlights the urgent need for effective therapies against this virus. The second section dives into the pathophysiology of viral infections, providing valuable insights into transmission dynamics and the essential role of testing and rapid detection methods. The third section examines antiviral agents and treatments, addressing the numerous challenges in drug design, the immune response, and vaccine development.
Finally, the fourth section tackles related issues such as co-infections in COVID-19 patients, the landscape of clinical trials, regulatory considerations, and future perspectives on antiviral therapies. With contributions from an international group of experts, this book offers a well-rounded understanding of the ongoing battle against SARS-CoV-2 and the COVID-19 disease it causes.
Finally, the fourth section tackles related issues such as co-infections in COVID-19 patients, the landscape of clinical trials, regulatory considerations, and future perspectives on antiviral therapies. With contributions from an international group of experts, this book offers a well-rounded understanding of the ongoing battle against SARS-CoV-2 and the COVID-19 disease it causes.
Key features
Key features
- Provides a detailed introduction to SARS-CoV-2 and the development of viral therapies for better understanding the complexities of viral infections and their treatment
- Explores the pathophysiology of SARS-CoV-2 infections, including how the virus interacts with host receptors, mutations, and the immune system's adaptation to the virus
- Discusses the development of novel antiviral agents, vaccines, and therapeutic regimens designed specifically to combat SARS-CoV-2 and its variants
- Examines the evolving landscape and potential future direction of COVID-19 treatment options
Readership
Readership
Researchers, scientists, academics, postgraduate students, doctoral and postdoctoral research fellows, and industry professionals in Microbiology, Virology, Medical, Biomedical Sciences, Pharmaceutical Sciences, and Biotechnology
Table of contents
Table of contents
SECTION I: INTRODUCTION
1. Introduction to SARS-CoV-2 therapy
SECTION II: VIRAL INFECTIONS, TRANSMISSION, AND TESTING
2. Pathophysiology of SARS-CoV-2 viral infections
3. Quantification of SARS-CoV-2 in wastewater
4. Understanding interaction between SARS-CoV-2 spike receptor-binding domain and surface receptors for drug design against SARS-CoV-2
5. Mutations of SARS-CoV-2
6. Resistance of SARS-CoV-2 to therapeutic agents
7. Adaptation of SARS-CoV-2 to immune system
8. Impact of comorbidity in SARS- CoV-2 infection
9. Role of T Cells in the SARS-CoV-2 infection
10. Rapid detection of SARS-CoV-2 infection
SECTION III: ANTIVIRAL AGENTS AND THERAPEUTICS
11. Challenges in designing SARS-CoV-2 antiviral agents
12. Innate and adaptive immune responses in SARS-CoV-2 infection
13. The role of Vitamin D in the SARS-CoV-2 infection
14. Novel approach towards therapeutic regimen against SARS-CoV-2 infection
15. Development of targeted antiviral with particular reference to SARS-CoV-2
16. Development of SARS-CoV-2 vaccine
17. Development of mRNA vaccines and modification of formulation for administering in multiple routes against SARS-CoV-2
18. Role of natural polysaccharides against COVID-19
19. Monoclonal antibodies cocktail for the treatments of COVID-19
20. Importance of nutraceuticals in fighting SARS-CoV-2
21. Herbal drugs to combat SARS-CoV-2 virus
22. Role of plasma therapy in the management of SARS-CoV-2 viral infections
23. Intranasal vaccines for SARS-CoV-2
24. Preclinical studies of a receptor – binding domain (RBD) –based recombinant protein vaccine on animal model (with particular reference to SARS- CoV-2)
SECTION IV: OTHER RELATED TOPICS
25. Mucormycosis – a serious problem in COVID-19 patients
26. Clinical trials and regulatory considerations of SARS-CoV-2 antiviral agents
27. Market overview of SARS-CoV-2 antiviral drugs
28. Future perspectives of SARS-CoV-2 antiviral therapy
1. Introduction to SARS-CoV-2 therapy
SECTION II: VIRAL INFECTIONS, TRANSMISSION, AND TESTING
2. Pathophysiology of SARS-CoV-2 viral infections
3. Quantification of SARS-CoV-2 in wastewater
4. Understanding interaction between SARS-CoV-2 spike receptor-binding domain and surface receptors for drug design against SARS-CoV-2
5. Mutations of SARS-CoV-2
6. Resistance of SARS-CoV-2 to therapeutic agents
7. Adaptation of SARS-CoV-2 to immune system
8. Impact of comorbidity in SARS- CoV-2 infection
9. Role of T Cells in the SARS-CoV-2 infection
10. Rapid detection of SARS-CoV-2 infection
SECTION III: ANTIVIRAL AGENTS AND THERAPEUTICS
11. Challenges in designing SARS-CoV-2 antiviral agents
12. Innate and adaptive immune responses in SARS-CoV-2 infection
13. The role of Vitamin D in the SARS-CoV-2 infection
14. Novel approach towards therapeutic regimen against SARS-CoV-2 infection
15. Development of targeted antiviral with particular reference to SARS-CoV-2
16. Development of SARS-CoV-2 vaccine
17. Development of mRNA vaccines and modification of formulation for administering in multiple routes against SARS-CoV-2
18. Role of natural polysaccharides against COVID-19
19. Monoclonal antibodies cocktail for the treatments of COVID-19
20. Importance of nutraceuticals in fighting SARS-CoV-2
21. Herbal drugs to combat SARS-CoV-2 virus
22. Role of plasma therapy in the management of SARS-CoV-2 viral infections
23. Intranasal vaccines for SARS-CoV-2
24. Preclinical studies of a receptor – binding domain (RBD) –based recombinant protein vaccine on animal model (with particular reference to SARS- CoV-2)
SECTION IV: OTHER RELATED TOPICS
25. Mucormycosis – a serious problem in COVID-19 patients
26. Clinical trials and regulatory considerations of SARS-CoV-2 antiviral agents
27. Market overview of SARS-CoV-2 antiviral drugs
28. Future perspectives of SARS-CoV-2 antiviral therapy
Product details
Product details
- Edition: 1
- Latest edition
- Published: April 1, 2027
- Language: English
About the editors
About the editors
AN
Amit Kumar Nayak
Amit Kumar Nayak (M. Pharm, Ph.D) is currently working as Professor at School of Pharmaceutical Sciences,Siksha ‘O' Anusandhan (Deemed to be University), Odisha, India. He has earned his PhD from IFTM University, Moradabad, Uttar Pradesh, India. He has over 14 years of research experiences in the field of pharmaceutics, especially in the development and characterization of novel biopolymeric and nanostructured drug delivery systems. Till date, he has authored more than 138 research and review publications in various high-impact peer-reviewed journals and 135 book chapters. He has edited/authored 23 international books to his credit. Dr. Nayak has presented his research work at several conferences. He has received University Foundation Day Research Award, 2019 and 2022 by Biju Patnaik University of Technology, Odisha. Dr. Nayak is a life member of the Association of Pharmaceutical Teachers of India (APTI) and a registered pharmacist.
Affiliations and expertise
Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, IndiaAD
Amal Kumar Dhara
Dr. Amal Kumar Dhara has over 27 years of teaching and research experience in Pharmacology and Toxicology, with expertise in neuropharmacology, anti-inflammatory, antiulcer, and free radical scavenging activities of Indian medicinal plants. He earned his PhD in Pharmaceutical Sciences from Jadavpur University, Kolkata, West Bengal, India. Dr. Dhara currently serves as Head of the Department (Pharmacy) at Contai Polytechnic, Government of West Bengal, India. He has previously worked as a Production Executive at M/S Deys Medical Stores Mfg (UP) Ltd., Uttar Pradesh, for over three years. Dr. Dhara has authored more than ten research and review papers in reputed journals, along with fifteen book chapters and five books. He has presented his work at national and international conferences and is a life member of the Indian Pharmaceutical Association and Indian Pharmacological Society, as well as a registered pharmacist.
Affiliations and expertise
Department of Pharmacy, Contai Polytechnic, Government of West Bengal, Contai, Purba Medinipur, West Bengal, India